daratumumab in the treatment of mm with high-risk cytogenetics
Published 4 years ago • 219 plays • Length 3:57Download video MP4
Download video MP3
Similar videos
-
5:07
daratumumab in the management of al amyloidosis
-
3:36
daratumumab practical considerations in mm
-
1:04
long-term survival outcomes in pts with mf treated with momelotinib vs danazol in the momentum trial
-
1:53
exploring daratumumab as a treatment option for patients with t-all
-
1:04
revolutionizing mm treatment with daratumumab
-
4:13
daratumumab as maintenance therapy after autosct in patients with multiple myeloma
-
13:43
darzalex® iv (daratumumab) mechanism of action for multiple myeloma
-
15:09
subcutaneous daratumumab — dr. jonathan kaufman | mcrt webcast july 11
-
2:30
daratumumab and isatuximab in the treatment of multiple myeloma
-
4:22
optimizing treatment sequencing in multiple myeloma: daratumumab upfront versus subsequent lines
-
3:10
is there a benefit to rituximab maintenance after first-line bendamustine-rituximab for mcl?
-
1:58
treatment options for patients with multiple myeloma who are resistant to daratumumab
-
1:05
daratumumab: no evidence of disease after treatment?
-
2:39
subcutaneous daratumumab: an update on the latest mm clinical trials
-
2:21
the role of daratumumab in the treatment of myeloma and insights into the maia trial
-
2:08
novel drug delivery method to prevent daratumumab infusion-related reactions in mm
-
2:41
optimizing the use of daratumumab in al amyloidosis
-
1:19
moving towards a daratumumab standard of care in mm
-
2:00
an update on the genomic landscape of mm
-
1:10
latest developments in the treatment of emd in myeloma
-
1:55
the real-world efficacy of brentuximab vedotin consolidation post-autosct in r/r hl
-
2:18
rapid daratumumab infusion for mm